Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0151814 (
coronary occlusion
)
3,687
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Patients with
bicuspid
aortic valve disease have systematically been excluded from large randomized clinical trials investigating transcatheter aortic valve implantation (TAVI) due to their younger age, lower surgical risk and complex aortic anatomy. The asymmetric nature of the
bicuspid
valve orifice often accompanied by heavy regional calcification has led to concerns regarding valve positioning and expansion.
Bicuspid aortic valve
disease patients are at heightened risk of TAVI-related complications including
coronary occlusion
, aortic dissection and annular rupture, as well as the known risks of progressive aortopathy in these patients. These unique anatomical characteristics pose challenges for TAVI operators. However, with recent and ongoing refinements in implantation technique, improvements in pre-procedural imaging and iterations in device design, TAVI is emerging as a safe and feasible treatment option in this population. Paravalvular aortic regurgitation and high pacemaker rates have been the Achilles Heel for TAVI in
bicuspid
valve patients, yet newer generation devices are yielding promising results. Further studies are required before TAVI ultimately emerges as a viable option in low and intermediate surgical-risk patients with
bicuspid
valve disease. This review comprehensively summarizes the epidemiology, pathology and current evidence for TAVI in patients with
bicuspid
aortic valve disease. We also outline some practical tips for performing TAVI in these patients.
...
PMID:Transcatheter Treatment of Bicuspid Aortic Valve Disease: Imaging and Interventional Considerations. 3007 70
Despite the landmark release of recent transcatheter aortic valve replacement data, the gold standard of surgical therapy is here to stay. Surgery remains vital in patient populations with low coronary height raising risk of
coronary occlusion
, aneurysmal ascending aorta, isolated aortic regurgitation, noncalcific disease,
bicuspid
valves, and multivessel coronary disease, or other structural abnormality requiring cardiac surgery. Consideration of these issues highlights the ongoing importance of multidisciplinary consideration of individual patient cases, careful review of imaging, and preservation of a robust surgical program to complement transcatheter development. As the landscape of valvular heart disease management continues to evolve, the surgeon's role is changing, but by no means diminished and their engagement in heart team decision making remains paramount.
...
PMID:The importance of surgical therapy with expansion of TAVR to low-risk patients. 3169 40